| Name | Title | Contact Details |
|---|
Cybrdi is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
M H Monteal Biotechnologies is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fullpower is the leader for cloud-based IoT smart-home and wearable solutions powered by AI, machine-learning and data science. With more than 125 patents, the Fullpower IP portfolio covers the AI-powered Sleeptracker® and the MotionX® IoT technology platforms for the Smart-Home and wearable. Fullpower`s business model is to license technology and IP to brand leaders such as Nike, BeautyRest, Amazon, Movado, Serta and others. Founded by Philippe Kahn, creator of the first camera-phone and based in Silicon Valley, the Fullpower team is passionate about technology craftsmanship, innovation, and the global AI-IoT paradigm shift.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.